EUCTR2015-005439-41-PL进行中（未招募）1 期
EVALUATION OF EFFICACY AND SAFETY OF OBINUTUZUMAB PREEMPTIVE TREATMENT AT THE TIME OF THE MOLECULAR RELAPSE AFTER FIRST LINE IMMUNOCHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANTATION IN MANTLE CELL LYMPHOMA PATIENTS. OPERA PLRG-10 TRIAL (ML29157) - OPERA PLRG-10 TRIAL (ML29157)
Polish Lymphoma Research Group (PLRG)0 个研究点目标入组 60 人开始时间: 2017年6月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with evidence of MCL molecular relapse in peripheral blood or/and bone marrow
- •- Diagnosis of mantle cell lymphoma confirmed by histopathology [if necessary, confirmed by FISH (CCND1)]
- •- Presence of clone-specific immunoglobulin heavy chain (IGH) gene
- •rearrangements or BCL1-IGH fusion gene as a molecular marker used
- •for minimal residual disease (MRD) assessment
- •- Patients who achieved a molecular remission after first-line treatment
- •with myeloablative consolidation and ASCT
- •- Patients without evidence of mantle cell lymphoma progression/relapse
- •according to the Lugano Classification criteria (2014)
- •- ECOG performance status = 2
- •- Signed patient’s informed consent form
- •- Survival prognosis > 6 months
- •- Women of childbearing potential must have a negative pregnancy test
- •result prior to initiation of treatment with the study medication and must
- •consent to undergo pregnancy tests during the treatment period.
- •- Women of child-bearing potential must consent either to sexual
- •abstinence or to using effective contraception (that results in a failure
- •rate of < 1% per year) while receiving the study medication and for 18
- •months after its discontinuation.
- •- Men must consent either to using an acceptable contraception method
- •(that results in a failure rate of < 1% per year) or continued sexual
- •abstinence while receiving the study medication and for 6 months after
- •its discontinuation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Central nervous system involvement
- •- Chemotherapy, radiation therapy or any other antineoplastic treatment (including steroids, monoclonal antibodies or medications at the stage of clinical studies, before receiving marketing authorization) after ASCT and before administration of the study medication
- •- Major surgery within 28 days prior to the study treatment initiation
- •- Renal impairment (plasma creatinine concentration > 1.5 × upper limit of normal and/or creatinine clearance = 40 ml/min)
- •- Hepatic impairment (total bilirubin concentration > 1.5 × upper limit of normal, AST and ALT > 2.5 × upper limit of normal)
- •- Hb< 9 g/dl, ANC < 1.5 G/l, platelets < 75 G/l
- •- International normalized ratio (INR) > 1.5
- •- Clinically significant heart disease, including uncontrolled arrhythmias, unstable coronary artery disease, serious congestive circulatory failure (NYHA III–IV), myocardial infarction within 6 months before enrolment
- •- Other comorbidities, not responding to treatment, including, but not limited to: hematopoietic system diseases, gastrointestinal system diseases, endocrine system diseases, respiratory system diseases, neurological diseases, cerebral diseases and mental diseases that could affect compliance with the protocol or interpretation of results
- •- Active infections (viral, bacterial, fungal)
- •- Coexistence of another neoplasm or a history of neoplastic disease (except for adequately treated basal cell carcinoma or squamous cell skin carcinoma, in situ cervical cancer or other neoplasm if the patient is in complete remission after at least 5 years of treatment discontinuation)
- •- Active HIV, HBV or HCV infection
- •- Positive test results for chronic hepatitis B. All patients must be tested for both HBsAg and HBcAb at screening, if either of the tests is positive, the patient is not eligible for inclusion in the trial. Patients who have protective titers of HBsAb after vaccination are eligible provided they are negative for both HBsAg and HBcAb
- •- Positive testing for hepatitis C (hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA
- •- Vaccination with live vaccines within 28 days prior to start of the preemptive treatment
- •- Known or suspected hypersensitivity to the study medication
- •- Women who are pregnant or breastfeeding
研究者
相似试验
进行中（未招募）
不适用
Study to determine the recommended dose, the safety and the efficacy of lenalidomide administered in association with obinutuzumab (GA101) for the treatment of relapsed/refractory B-cell Lymphoma.Phase IB: CD20 positive Follicular Lymphoma, WHO grade 1, 2 or 3a relapsed/refractory after =1 prior R-containing regimen Phase II: CD20 positive follicular and agressive B-cell lymphoma (Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma) relapsed/refractory after =1 prior R-containing regimenMedDRA version: 15.0Level: PTClassification code 10016906Term: Follicle centre lymphoma, follicular grade I, II, III refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005150-62-FRGELARC
进行中（未招募）
1 期
Study to determine the recommended dose, the safety and the efficacy of lenalidomide administered in association with obinutuzumab (GA101) for the treatment of relapsed/refractory B-cell Lymphoma.Phase IB: CD20 positive Follicular Lymphoma, WHO grade 1, 2 or 3a relapsed/refractory after =1 prior R-containing regimen Phase II: - CD20 positive follicular not previously treated- CD20 positive follicular relapsed/refractory after =1 prior R-containing regimen- agressive B-cell lymphoma (Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma) relapsed/refractory after =1 prior R-containing regimenMedDRA version: 21.0Level: PTClassification code 10016906Term: Follicle centre lymphoma, follicular grade I, II, III refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005150-62-BEYSARC291
终止
2 期
Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular RelapseMantle Cell LymphomaNCT03229382Polish Lymphoma Research Group1
招募中
2 期
Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16)JPRN-jRCTs041200063Toshihiro Miyamoto117
进行中（未招募）
1 期
A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphomarituximab refractory follicular lymphomaMedDRA version: 16.1 Level: LLT Classification code 10016896 Term: Follicle centre lymphoma diffuse small cell lymphoma NOS System Organ Class: 100000004864EUCTR2013-004635-69-NLVU University Medical Center25